Psychotic Disorders Program, University of Massachusetts Medical School/UMass Memorial Medical Center, Worcester, MA, USA.
Department of Psychiatry, The1st Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Acta Psychiatr Scand. 2017 Nov;136(5):465-472. doi: 10.1111/acps.12799. Epub 2017 Aug 29.
This study examined the effect of adjunctive telmisartan on psychopathology and cognition in olanzapine- or clozapine-treated patients with schizophrenia.
In a 12-week randomized, double-blind, placebo-controlled study, patients diagnosed with schizophrenia or schizoaffective disorder received either telmisartan (80 mg once per day) or placebo. Psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS) and the Scale for Assessment of Negative Symptoms (SANS), and a neuropsychological battery was used to assess cognitive performance. Assessments for psychopathology and cognition were conducted at baseline and week 12.
Fifty-four subjects were randomized, and 43 completed the study (22 in the telmisartan group, 21 in the placebo group). After 12-weeks of treatment, the telmisartan group had a significant decrease in PANSS total score compared withthe placebo group (mean ± SD: - 4.1 ± 8.1 vs. 0.4 ± 7.5, P = 0.038, SCohen's d = 0.57). There were no significant differences between the two groups in change from baseline to week 12 in PANSS subscale scores, SANS total score, or any cognitive measures (P > 0.100).
The present study suggests that adjunctive treatment with telmisartan may improve schizophrenia symptoms. Future trials with larger sample sizes and longer treatment durations are warranted.
本研究旨在探讨替米沙坦辅助治疗对奥氮平或氯氮平治疗的精神分裂症患者的精神病理学和认知功能的影响。
在一项为期 12 周的随机、双盲、安慰剂对照研究中，诊断为精神分裂症或分裂情感障碍的患者接受替米沙坦（80mg 每日一次）或安慰剂治疗。使用阳性和阴性症状量表（PANSS）和阴性症状评定量表（SANS）评估精神病理学，使用神经心理学成套测验评估认知表现。在基线和第 12 周进行精神病理学和认知评估。
共有 54 名受试者被随机分配，43 名完成了研究（替米沙坦组 22 名，安慰剂组 21 名）。经过 12 周的治疗，替米沙坦组的 PANSS 总分与安慰剂组相比有显著下降（平均 ± 标准差：-4.1 ± 8.1 对 0.4 ± 7.5，P = 0.038，SCohen's d = 0.57）。两组在 PANSS 分量表评分、SANS 总分或任何认知测量方面，从基线到第 12 周的变化均无显著差异（P > 0.100）。
本研究表明，替米沙坦辅助治疗可能改善精神分裂症症状。需要进行更大样本量和更长治疗时间的未来试验。
